Endocrinology Medical News about Diabetes Mellitus, Type 2

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

3. Rapid correction of low vitamin D status in nursing home residents

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Beyond Glycemic Control: Treating the Entire Type 2 Diabetes Disorder
Postgraduate Medicine, 10/05/09

Brunton S – Both effective glucose control and therapy to reduce cardiovascular risk factors, including overweight/obesity, are needed to prevent the complications of type 2 diabetes. Most conventional antidiabetes agents, including sulfonylureas, thiazolidinediones, and insulin, improve glycemic control but are associated with weight gain or, as with metformin, are weight–neutral or weight–sparing. The incretin–based therapies, such as the glucagon–like peptide–1 (GLP–1) receptor agonists and the dipeptidyl peptidase–4 inhibitors, have been shown to be safe and effective in lowering glucose while eliciting favorable effects on weight (ie, weight–reducing and weight–neutral, respectively). The effects of these agents on other parameters of cardiovascular risk are also being studied. Advances in GLP–1 receptor agonist therapy include development of agents with longer durations of activity allowing for more convenient dosing of therapies for patients with type 2 diabetes, which should lead to better patient compliance, adherence, and overall clinical outcomes.

<< Previous
Safety Nets Get Stimulus I.T. Funds

Next >>
Comparison of Prandial AIR Inhaled Insulin Alone to Intensified...